The Role of 5αR and α1AR Inhibitors in Management of BPH
September 2019
TLDR Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
The study reviewed the management of benign prostatic hyperplasia (BPH) using combination therapy involving 5α Reductase inhibitors (such as dutasteride or finasteride) and α1 adrenoreceptor blockers. It aimed to determine if this combination therapy was more effective than monotherapy. The research focused on the safety, efficacy, and development of these treatment agents. The study concluded that combination therapy could potentially offer superior benefits in managing BPH compared to using either treatment alone.
